Reality Check on Chronic Idiopathic Constipation
Market access for chronic idiopathic constipation treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 41% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In March 2020, the FDA approved Sebela Pharmaceuticals’ Pizensy (lactitol) for oral solution for the treatment of chronic idiopathic constipation in adults. Unlike solid oral treatments, the medication can be mixed with the patient’s fluid of choice, including water, juice, coffee, tea and soda
- Key Findings: This class is heavily contracted, with some PBMs excluding Trulance (plecanatide) in favor of the older therapies Linzess (linaclotide) and Amitiza (lubiprostone). All medications are priced equally, so contracting is key for product placement
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.